ReviewMolecular biology reports2025
Interplay between Nrf2 and ROS in regulating epithelial-mesenchymal transition: implications for cancer metastasis and therapy.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Disulfidptosis and its molecular mechanisms in cancer: mechanisms, regulation, and therapeutic potential.Medical oncology (Northwood, London, England) · 2026Review
- Review
- Xenobiotic Sulforaphane in Head and Neck Cancer: Beyond the Nrf2 Pathway.Journal of xenobiotics · 2026Review
- Mitophagy and Ubiquitination Coordinate Context-Specific Mitochondrial Quality Control and EMT/MET Plasticity to Drive Cancer Cell Invasion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Melatonin in Integrative Oncology: Biological Mechanisms, Therapeutic Evidence and Implementation Strategies.Oncology research · 2026Review
- Machine learning-driven comprehensive profiling of tumor heterogeneity and sialylation in hepatocellular carcinoma.NPJ precision oncology · 2025Article
- Effects of the Pharmacological Modulation of NRF2 in Cancer Progression.Medicina (Kaunas, Lithuania) · 2025Review
- Review
- Linolenic Acid Inhibits Cancer Stemness and Induces Apoptosis by Regulating Nrf2 Expression in Gastric Cancer Cells.Current issues in molecular biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Epithelial-mesenchymal transition (EMT), including developmental (Type I), wound healing (Type II), and pathological (Type III) subtypes, constitutes a critical driver of cancer metastasis. This review analyzes the redox interplay between nuclear factor erythroid 2-related factor 2 (Nrf2) and reactive oxygen species (ROS) in EMT regulation and cancer progression. Nrf2 maintains redox homeostasis through antioxidant gene activation while paradoxically promoting tumor survival and drug resistance via Keap1-dependent degradation and phosphorylation-mediated stabilization. ROS generated through mitochondrial and NADPH oxidase pathways exhibit dual functionality: moderate levels activate EMT transcription factors to drive metastasis and cancer stem cells (CSCs) plasticity, whereas excessive ROS induce apoptosis and ferroptosis. While Nrf2 typically suppresses EMT through ROS neutralization and epithelial integrity preservation, chronic Nrf2 activation in CSCs paradoxically sustains metastatic potential through redox buffering. This synthesis delineates the spatiotemporal regulation of Nrf2-ROS-EMT networks across tumor microenvironments, emphasizing therapeutic opportunities through redox balance modulation and pathway-specific Nrf2 inhibition in advanced malignancies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.